Abre Venous Self-expanding Stent System
Medtronic Vascular, Inc. · Decision date Apr 8, 2026
What did the FDA decide?
FDA records P200026/S017 as a supplement to PMA P200026, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 8, 2026.
FDA approval order statement
an additional repacking site and minor changes to the repack process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 8, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P200026/S017
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular, Inc.
- Product code
- QAN
- Decision code
- OK30
- Decision date
- Apr 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, iliac vein.
- Applicant
- Medtronic Vascular, Inc.
- Product code
- QAN
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200026. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200026 · Original PMA
Abre Venous Self-expanding Stent System
P200026/S014 · Related supplement
Abre Venous Self-expanding Stent System
P200026/S015 · Related supplement
Abre Venous Self-expanding Stent System
P200026/S016 · Related supplement
Abre Venous Self-expanding Stent System
P200026/S017 received
Application receipt date recorded by FDA.
P200026/S017 · FDA decision
30-Day Notice
P200026/S018 · Related supplement
Abre Venous Self-expanding Stent System
P200026/S019 · Related supplement
Abre Venous Self-Expanding Stent System
P200026/S020 · Related supplement
Abre Venous Self-expanding Stent System
Timeline entries are records held by MedtechLedger for P200026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA approval | Oct 21, 2020 | FDA | |
Abre Venous Self-expanding Stent SystemP200026/S014 | Medtronic Vascular, Inc. | PMA supplement | Sep 23, 2025 | FDA |
Abre Venous Self-expanding Stent SystemP200026/S015 | Medtronic Vascular, Inc. | PMA supplement | Dec 12, 2025 | FDA |
Abre Venous Self-expanding Stent SystemP200026/S016 | Medtronic Vascular, Inc. | PMA supplement | Mar 23, 2026 | FDA |
Abre Venous Self-expanding Stent SystemP200026/S018 | Medtronic Vascular, Inc. | PMA supplement | Apr 27, 2026 | FDA |
Abre Venous Self-Expanding Stent SystemP200026/S019 | Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA |
Abre Venous Self-expanding Stent SystemP200026/S020 | Medtronic Vascular, Inc. | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code QAN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Duo Venous Stent SystemP230021/S004 | Philips Image Guided Therapy Corporation | PMA supplement | Aug 26, 2026 | FDA |
Venovo Venous Stent SystemP180037/S015 | Bard Peripheral Vascular, Inc. | PMA supplement | Jun 10, 2026 | FDA |
Zilver Vena Venous Self-Expanding StentP200023/S009 | Cook Ireland, Ltd. | PMA supplement | Apr 14, 2026 | FDA |
Duo Venous Stent SystemP230021/S003 | Philips Image Guided Therapy Corporation | PMA supplement | Feb 12, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3033 Campus Dr., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P200026/S017
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




